Table III.

Reductions in Mean SBP and DBP Observed After 8 Weeks of Treatment With HCTZ Monotherapy in the Factorial Studies*

		Mean Absolute Change inBP (mm Hg)		Mean Placebo‐Corrected Change in BP (mm Hg)
Factorial Studies	Hctz Doses	DBP	SBP	DBP	SBP
Irbesartan 22	Placebo	−3.5	−2.3	…	…
	6.25 mg	−5.1	−4.6	−1.6	−2.3
	12.5 mg	−6.2	−8.9	−2.7	−6.6
	25 mg	−8.3	−11.5	−4.8	−9.2
Olmesartan 23	Placebo	−8.2	−3.3	…	…
	12.5 mg	−10.2	−9.6	−2.0	−6.3
	25 mg	−12.9	−17.1	−4.7	−13.8
Telmisartan** 24	Placebo	−3.8	−2.9	…	…
	12.5 mg	−7.3	−6.9	−3.5	−4.0
Valsartan 25 , 41	Placebo	−4.1	−1.9	…	…
	12.5 mg	−7.1	−7.3	−3.0	−5.4
	25 mg	−9.3	−12.7	−5.2	−10.8
SBP=systolic blood pressure; DBP=diastolic blood pressure; HCTZ=hydrochlorothiazide; BP=blood pressure; *data are mean changes in DBP and SBP at end point (or last observation carried forward) in the intent‐to‐treat population for studies involving olmesartan, telmisartan, and valsartan; the irbesartan study provided data on the population of patients who completed the study and/or had Week 8 BP readings; **the telmisartan study used supine BP measurements and the other studies used sitting BP measurements.